Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors

References

• Bhat GR, Hyole RG, Li J. Head and neck cancer: current challenges and future perspectives. Adv Cancer Res. 2021;152:67–12.
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22. doi:10.1038/nrc2982.
   PubMed Web of Science ®Google Scholar
• Näsman A, Du J, Dalianis T. A global epidemic increase of an HPV-induced tonsil and tongue base cancer - potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020;287(2):134–152. doi:10.1111/joim.13010.
   PubMed Web of Science ®Google Scholar
• Borel C, Jung AC, Burgy M. Immunotherapy breakthroughs in the treatment of recurrent or metastatic head and neck squamous cell carcinoma. Cancers (Basel). 2020;12(9):2691. doi:10.3390/cancers12092691.
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr., Psyrri A, Basté N, Neupane P, Bratland Å, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-7.
   PubMed Web of Science ®Google Scholar
• Clarke E, Eriksen JG, Barrett S. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis. Acta Oncol. 2021;60(1):1–9. doi:10.1080/0284186X.2020.1867766.
   PubMedGoogle Scholar
• Botticelli A, Zizzari IG, Scagnoli S, Pomati G, Strigari L, Cirillo A, Cerbelli B, Di Filippo A, Napoletano C, Scirocchi F, et al. The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study. J Pers Med. 2021;11(7):651. doi:10.3390/jpm11070651.
   PubMed Web of Science ®Google Scholar
• Kluckova K, Durmanova V, Bucova M. Soluble HLA-G, its diagnostic and prognostic value and potential target molecule for future therapy in cancer. Bratisl Lek Listy. 2021;122(9):60–617. doi:10.4149/BLL_2021_097.
   PubMedGoogle Scholar
• Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7(1):10501. doi:10.1038/ncomms10501.
   PubMed Web of Science ®Google Scholar
• Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019;8(4):e1564505. doi:10.1080/2162402X.2018.1564505.
   PubMed Web of Science ®Google Scholar
• Navarro P, Martínez-Bosch N, Blidner AG, Rabinovich GA. Impact of galectins in resistance to anticancer therapies. Clin Cancer Res. 2020;26(23):6086–6101. doi:10.1158/1078-0432.CCR-18-3870.
   PubMed Web of Science ®Google Scholar
• Johannes L, Jacob R, Leffler H. Galectins at a glance. J Cell Sci. 2018;131(9). doi:10.1242/jcs.208884.
   PubMed Web of Science ®Google Scholar
• Popa SJ, Stewart SE, Moreau K. Unconventional secretion of annexins and galectins. Semin Cell Dev Biol. 2018;83:42–50. doi:10.1016/j.semcdb.2018.02.022.
   PubMed Web of Science ®Google Scholar
• Chou FC, Chen HY, Kuo CC, Sytwu HK. Role of galectins in tumors and in clinical immunotherapy. Int J Mol Sci. 2018;19(2):430. doi:10.3390/ijms19020430.
   PubMed Web of Science ®Google Scholar
• Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun. 2017;8(1):793. doi:10.1038/s41467-017-00925-6.
   PubMedGoogle Scholar
• Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F. Blood diffusion and Th1-suppressive effects of galectin-9–containing exosomes released by Epstein-Barr virus–infected nasopharyngeal carcinoma cells. Blood. 2009;113(9):1957–1966. doi:10.1182/blood-2008-02-142596.
   PubMed Web of Science ®Google Scholar
• Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, Wang Z, Rangan VS, Jiang D, von Eyben R, et al. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Invest. 2019;129(12):5553–5567. doi:10.1172/JCI129025.
   PubMed Web of Science ®Google Scholar
• Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, Toubeau G, Decaestecker C, Kiss R. The determination of the levels of circulating galectin-1 and −3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol. 2008;44(1):86–93. doi:10.1016/j.oraloncology.2006.12.014.
   PubMed Web of Science ®Google Scholar
• de Oliveira JT, Ribeiro C, Barros R, Gomes C, de Matos AJ, Reis CA, Rutteman GR, Gärtner F. Hypoxia up-regulates galectin-3 in mammary tumor progression and metastasis. PLoS One. 2015;10(7):e0134458. doi:10.1371/journal.pone.0134458.
   PubMed Web of Science ®Google Scholar
• Gu X, Meng H, Wang J, Wang R, Cao M, Liu S, Chen H, Xu Y. Hypoxia contributes to galectin-3 expression in renal carcinoma cells. Eur J Pharmacol. 2021;890:173637. doi:10.1016/j.ejphar.2020.173637.
   PubMed Web of Science ®Google Scholar
• Wang L, Li YS, Yu LG, Zhang XK, Zhao L, Gong FL, Yang XX, Guo XL. Galectin-3 expression and secretion by tumor-associated macrophages in hypoxia promotes breast cancer progression. Biochem Pharmacol. 2020;178:114113. doi:10.1016/j.bcp.2020.114113.
   PubMed Web of Science ®Google Scholar
• Darrow AL, Shohet RV. Galectin-3 deficiency exacerbates hyperglycemia and the endothelial response to diabetes. Cardiovasc Diabetol. 2015;14(1):73. doi:10.1186/s12933-015-0230-3.
   PubMedGoogle Scholar
• Chang H, Xu Q, Li J, Li M, Zhang Z, Ma H, Yang X. Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC. Cell Death Dis. 2021;12(8):725. doi:10.1038/s41419-021-03990-4.
   PubMed Web of Science ®Google Scholar
• Duchemann B, Remon J, Naigeon M, Mezquita L, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin E, et al. Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer. Cancers (Basel). 2020;12(12):3625.
   PubMed Web of Science ®Google Scholar
• Bellutti Enders F, van Wijk F, Scholman R, Hofer M, Prakken BJ, van Royen-Kerkhof A, de Jager W. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis. Arthritis Rheumatol. 2014;66(8):2281–2289. doi:10.1002/art.38676.
   PubMed Web of Science ®Google Scholar
• Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, et al. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget. 2018;9(68):32984–32996. doi:10.18632/oncotarget.26034.
   PubMedGoogle Scholar
• Yogasundaram H, Nikhanj A, Putko BN, Boutin M, Jain-Ghai S, Khan A, Auray-Blais C, West ML, Oudit GY. Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction. J Am Heart Assoc. 2018;7(21):e009098. doi:10.1161/JAHA.118.009098.
   PubMed Web of Science ®Google Scholar
• Zhao CN, Mao YM, Liu LN, Wu Q, Dan YL, Pan HF. Plasma galectin-3 levels do not differ in systemic lupus erythematosus patients. Int J Rheum Dis. 2019;22(10):1820–1824. doi:10.1111/1756-185X.13677.
   PubMed Web of Science ®Google Scholar
• Tsugawa H, Tsujimoto Y, Sugitate K, Sakui N, Nishiumi S, Bamba T, Fukusaki E. Highly sensitive and selective analysis of widely targeted metabolomics using gas chromatography/triple-quadrupole mass spectrometry. J Biosci Bioeng. 2014;117(1):122–128. doi:10.1016/j.jbiosc.2013.06.009.
   PubMed Web of Science ®Google Scholar
• Viltard M, Durand S, Pérez-Lanzón M, Aprahamian F, Lefevre D, Leroy C, Madeo F, Kroemer G, Friedlander G. The metabolomic signature of extreme longevity: naked mole rats versus mice. Aging (Albany NY). 2019;11(14):4783–4800. doi:10.18632/aging.102116.
   PubMedGoogle Scholar
• «World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects». JAMA. 2013;310:2191–2194. DOI:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• Garneau JC, Bakst RL, Miles BA. Hypopharyngeal cancer: a state of the art review. Oral Oncol. 2018;86:244–250. doi:10.1016/j.oraloncology.2018.09.025.
   PubMed Web of Science ®Google Scholar
• Mito I, Takahashi H, Kawabata-Iwakawa R, Ida S, Tada H, Chikamatsu K. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma. Sci Rep. 2021;11(1):16134. doi:10.1038/s41598-021-95718-9.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2007;318(5853):1141–1143. doi:10.1126/science.1148536.
   PubMed Web of Science ®Google Scholar
• Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230(1):160–171. doi:10.1111/j.1600-065X.2009.00794.x.
   PubMed Web of Science ®Google Scholar
• Sundblad V, Morosi LG, Geffner JR, Rabinovich GA. Galectin-1: a Jack-of-All-Trades in the resolution of acute and Chronic inflammation. J Immunol. 2017;199(11):3721–3730. doi:10.4049/jimmunol.1701172.
   PubMed Web of Science ®Google Scholar
• Valdes M, Villeda J, Mithoowani H, Pitre T, Chasen M. Inflammatory markers as prognostic factors of recurrence in advanced-stage squamous cell carcinoma of the head and neck. Curr Oncol. 2020;27(3):135–141. doi:10.3747/co.27.5731.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom AA. Targeting interferon-γ in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021;17(11):678–691. doi:10.1038/s41584-021-00694-z.
   PubMed Web of Science ®Google Scholar
• Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62:2493–2497.
   PubMed Web of Science ®Google Scholar
• Coppock JD, Mills AM, Stelow EB. Galectin-3 expression in high-Risk HPV-positive and negative head & neck squamous cell carcinomas and regional lymph node metastases. Head Neck Pathol. 2021;15(1):163–168. doi:10.1007/s12105-020-01195-3.
   PubMed Web of Science ®Google Scholar
• Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL, Wu M, Wainwright DA. IDO1 in cancer: a Gemini of immune checkpoints. Cell Mol Immunol. 2018;15(5):447–457. doi:10.1038/cmi.2017.143.
   PubMed Web of Science ®Google Scholar
• Castro-Portuguez R, Sutphin GL. Kynurenine pathway, NAD(+) synthesis, and mitochondrial function: targeting tryptophan metabolism to promote longevity and healthspan. Exp Gerontol. 2020;132:110841. doi:10.1016/j.exger.2020.110841.
   PubMed Web of Science ®Google Scholar
• Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198. doi:10.4049/jimmunol.0903670.
   PubMed Web of Science ®Google Scholar
• Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11(1):4011. doi:10.1038/s41467-020-17750-z.
   PubMed Web of Science ®Google Scholar
• Bishnupuri KS, Alvarado DM, Khouri AN, Shabsovich M, Chen B, Dieckgraefe BK, Ciorba MA. IDO1 and kynurenine pathway metabolites activate PI3K-Akt signaling in the neoplastic colon epithelium to promote cancer cell proliferation and inhibit apoptosis. Cancer Res. 2019;79(6):1138–1150. doi:10.1158/0008-5472.CAN-18-0668.
   PubMed Web of Science ®Google Scholar
• Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52(1):183–199.e189. doi:10.1016/j.immuni.2019.11.014.
   PubMed Web of Science ®Google Scholar
• Kotwall C, Sako K, Razack MS, Rao U, Bakamjian V, Shedd DP. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154(4):439–442. doi:10.1016/0002-9610(89)90020-2.
   PubMed Web of Science ®Google Scholar
• Rodrigo JP, Suárez C, González MV, Lazo PS, Ramos S, Coto E, Alvarez I, García LA, Martínez JA. Variability of genetic alterations in different sites of head and neck cancer. Laryngoscope. 2001;111(7):1297–1301. doi:10.1097/00005537-200107000-00029.
   PubMed Web of Science ®Google Scholar
• Répássy G, Forster-Horváth C, Juhász A, Adány R, Tamássy A, Tímár J. Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. Pathol Oncol Res. 1998;4(1):14–21. doi:10.1007/BF02904689.
   PubMedGoogle Scholar
• Dardalhon V, Anderson AC, Karman J, Apetoh L, Chandwaskar R, Lee DH, Cornejo M, Nishi N, Yamauchi A, Quintana FJ, et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immun. 2010;185(3):1383–1392. doi:10.4049/jimmunol.0903275.
   PubMed Web of Science ®Google Scholar
• Zhang CX, Huang DJ, Baloche V, Zhang L, Xu JX, Li BW, Zhao XR, He J, Mai HQ, Chen QY, et al. Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. Oncogenesis. 2020;9(7):65. doi:10.1038/s41389-020-00248-0.
   PubMed Web of Science ®Google Scholar